Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Overview
Pacira BioSciences Inc (NASDAQ: PCRX) is a specialty pharmaceutical company committed to revolutionizing pain management by offering innovative non-opioid therapies and regenerative health solutions. With a core focus on providing safe and effective alternatives for pain control, the company leverages its proprietary drug delivery platforms to address acute pain in surgical and chronic conditions. Its approach combines advanced pharmaceutical formulations with novel medical devices, ensuring that clinicians have access to effective treatment options that reduce reliance on opioids.
Core Technologies and Products
At the heart of Pacira's innovation is its unique product delivery technology, which encapsulates active compounds without altering their molecular structures. This platform enables controlled, extended release of medications, ensuring long-lasting efficacy. The company has successfully commercialized several non-opioid treatments:
- EXPAREL: A long-acting local anesthetic designed to provide postsurgical pain control through sustained drug release, thereby reducing the need for opioids.
- ZILRETTA: An extended-release intra-articular injection indicated for the management of osteoarthritis knee pain, offering patients prolonged relief.
- iovera®: A handheld, drug-free device that applies controlled doses of cold therapy to targeted nerves, providing immediate and lasting pain relief.
In addition to these commercial products, Pacira is advancing its pipeline with a novel gene therapy candidate, PCRX-201. This locally administered therapy aims to treat osteoarthritis by regulating inflammatory pathways, thus addressing the root causes of pain and disability.
Market Position and Business Model
Pacira BioSciences operates at the intersection of innovative drug delivery and non-opioid pain management solutions. Its business model emphasizes:
- Commercialization of Proven Therapies: The company has established a presence in markets requiring effective postsurgical and chronic pain management solutions, evidenced by the wide adoption of its therapies in diverse clinical settings.
- Advanced R&D and Pipeline Development: By investing in robust research and development programs, along with strategic partnerships, Pacira continues to expand its portfolio and maintain competitive differentiation in the specialty pharmaceutical sector.
- Regulatory and Reimbursement Strategies: With products that have secured critical reimbursement designations, Pacira enhances market access for its non-opioid therapies across different healthcare settings. This strategic emphasis supports clinician adoption and broader patient access.
Clinical and Commercial Significance
The company's focus on non-opioid pain management comes at a time when reducing opioid dependency is an urgent priority in healthcare. By developing treatments that not only manage pain effectively but also minimize opioid consumption, Pacira is addressing a key public health challenge. Its clinically validated products have been incorporated into pain management protocols in hospitals and outpatient settings alike, offering enduring benefits for patients and healthcare providers.
Innovative Edge and Future Pipeline
Pacira’s utilization of advanced drug delivery systems, such as multivesicular liposomes and precise cryoneurolysis, underscores its commitment to innovation. These technologies not only improve therapeutic outcomes but also facilitate streamlined billing and regulatory approval processes through established coding systems. With an evolving pipeline that includes gene therapy approaches, the company is poised to expand its reach into additional therapeutic areas, addressing unmet needs in the treatment of chronic and musculoskeletal pain.
Competitive Landscape and Differentiators
In a competitive market, Pacira differentiates itself through its deep expertise in non-opioid pain management and its commitment to technological advancements. The integration of robust clinical data, strategic reimbursement initiatives, and a focus on delivering sustained therapeutic benefits positions the company as a trusted innovator among healthcare practitioners. Unlike traditional pain management solutions that rely heavily on opioids, Pacira’s products are designed to provide effective relief with reduced risk of dependency, offering a clinically superior alternative in the evolving landscape of pain management.
Conclusion
With a comprehensive portfolio that spans commercial-stage products and a promising pipeline, Pacira BioSciences Inc stands as a key player in the specialty pharmaceutical industry. Its ongoing commitment to developing non-opioid pain therapies, underpinned by advanced drug delivery technologies and rigorous clinical validation, ensures that it remains an authoritative source of innovation and expertise in pain management and regenerative health.
Pacira BioSciences partnered with the National Senior Games Association to achieve a GUINNESS WORLD RECORDS title for the Largest Game of Freeze Dance, held on May 16, 2022, with 1,308 participants in Fort Lauderdale, Florida. This event highlighted the company's non-opioid pain relief device, iovera°, which provides up to 90 days of osteoarthritis pain relief. Amber Sears from Pacira emphasized the initiative's role in promoting non-opioid options for chronic pain management, aiming to educate patients about viable alternatives to opioid treatments.
Pacira BioSciences reported preliminary net product sales for April 2022, with EXPAREL achieving $44.8 million, marking a 109% increase in average daily sales compared to April 2021. Sales of iovera° were $1.1 million, down from $1.5 million in the previous year. The company remains financially strong with an adjusted EBITDA of $53.8 million for Q1 2022. Despite ongoing pandemic-related challenges impacting elective surgeries, Pacira's leadership anticipates robust revenue growth. The company has not provided 2022 financial guidance due to uncertainties surrounding COVID-19.
TAMPA, Fla., May 10, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences (NASDAQ: PCRX) will participate in two upcoming healthcare conferences:
- RBC Capital Markets Global Healthcare Conference on May 17 at 8:00 AM ET.
- H.C. Wainwright Global Virtual Investment Conference on May 24 at 7:00 AM ET.
Live audio can be accessed on the company’s website, with replays available for two weeks post-events. Pacira's commitment lies in providing non-opioid pain management solutions.
Pacira BioSciences (Nasdaq: PCRX) reported a strong first quarter of 2022, with total revenues reaching $158 million, marking a 33% increase year-over-year. Net income was $6.8 million or $0.15 per share, while adjusted EBITDA stood at $53.8 million. Significant sales growth for EXPAREL at $129.2 million reflects operational resilience amid COVID-related challenges. The successful integration of the Flexion acquisition contributed to ZILRETTA's sales of $23.6 million. Looking forward, Pacira is optimistic about upcoming clinical studies and new product registrations.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will announce its first quarter financial results on May 4, 2022, before U.S. markets open. A conference call will follow at 8:30 a.m. ET, with participation options available for both domestic and international callers. The call will also be accessible via webcast on the company’s investor page. Pacira aims to provide non-opioid pain management solutions and has three commercial treatments: EXPAREL, ZILRETTA, and iovera, focusing on reducing opioid reliance.
Pacira BioSciences (Nasdaq: PCRX) announced record net product sales of EXPAREL totaling $51.2 million for March 2022, reflecting a 116% increase over March 2021. For Q1 2022, preliminary revenues range from $157.4 million to $158.4 million, up from $119.0 million in Q1 2021. Sales of ZILRETTA are estimated between $23.0 million and $24.0 million, down slightly from $24.6 million in Q1 2021. The company is not providing full-year 2022 revenue guidance due to ongoing uncertainties related to COVID-19's impact on elective surgeries.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in an analyst-led fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 8:45 AM ET. Interested parties can access the live audio on the company’s events page. A replay will be available for two weeks post-event.
Pacira focuses on providing non-opioid treatment options for patients, with commercial-stage products like EXPAREL®, ZILRETTA®, and ioveraº®. The company aims to redefine opioid use and addresses conditions involving the sympathetic nervous system.
Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net product sales for EXPAREL and iovera° for February 2022. EXPAREL sales reached $41.7 million, an increase of 17.2% from $35.6 million in February 2021, indicating average daily sales at 117% of the previous year. iovera° sales rose to $0.9 million, up from $0.7 million. The company noted ongoing challenges due to the COVID-19 pandemic impacting elective surgeries but did not provide financial guidance for 2022 due to uncertainties.
TAMPA, Fla., March 09, 2022 — Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in an analyst-led fireside chat at the Barclays Global Healthcare Conference on March 16, 2022, at 10:15 AM ET in Miami. Investors can listen to the live audio via the company's Events page, with a replay available for two weeks post-event. Pacira focuses on non-opioid treatments, offering products like EXPAREL for postsurgical pain management and ZILRETTA for osteoarthritis knee pain, aiming to reduce opioid reliance.
Pacira BioSciences (PCRX) reported record EXPAREL sales of $507 million for 2021, contributing to total revenues of $541.5 million, a 26% increase from 2020. The company achieved a GAAP net income of $42 million ($0.95 per share) but faced a GAAP net loss of $5.1 million in Q4 2021. Adjusted EBITDA for the year rose to $204 million. The acquisition of Flexion Therapeutics bolstered its non-opioid pain management portfolio. Looking ahead, Pacira refrained from providing 2022 revenue guidance due to ongoing COVID-19 impacts on elective surgeries.
FAQ
What is the current stock price of Pacira Biosciences (PCRX)?
What is the market cap of Pacira Biosciences (PCRX)?
What is the core focus of Pacira BioSciences Inc?
How does Pacira differentiate its products in the market?
What are the key commercial-stage products offered by Pacira?
What technology underpins Pacira's drug delivery system?
How does Pacira address the issue of opioid dependency?
What is PCRX-201 and what potential does it hold?
Which healthcare settings benefit from Pacira's therapies?
What role do reimbursement strategies play in Pacira's business model?
How does Pacira support clinical decision-making and patient care?
